What Is the Optimal Dose Of Ivermectin and Mebendazole To Treat Cancer?
There is no established or guideline-endorsed dose of ivermectin for cancer treatment, and all published experience comes from case reports, observational series, repurposed-drug programs, or extrapolation from preclinical studies
Consequently, dosing strategies vary considerably. The information below summarizes the most commonly reported approaches in integrative oncology practice, rather than a recommended standard of care.
Dosing Strategies Used in Multi-Drug Metabolic Programs
1. Continuous low-dose approach
This is the most commonly employed strategy in multi-drug metabolic protocols.
Typical dose:
- 0.2–0.4 mg/kg orally once daily
Examples:
- 60 kg person: 12–24 mg daily
- 70 kg person: 14–28 mg daily
- 80 kg person: 16–32 mg daily
- 90 kg person: 18–36 mg daily
The rationale is to provide continuous pressure on multiple pathways, including cancer stem-cell signaling, mitochondrial function, WNT/β-catenin, YAP/TAZ, and PAK1 signaling.
This is the dosing strategy which we prefer as a component of the multi-drug and 5-axis protocol.
2. Intermittent “pulse” dosing
Some clinicians favor intermittent dosing to reduce cumulative exposure.
Common schedules include:
- 0.4 mg/kg daily for 5 consecutive days every 2–4 weeks
- 0.4–0.6 mg/kg three times weekly
- 0.3–0.4 mg/kg Monday–Wednesday–Friday
The theoretical rationale is that intermittent exposure may preserve efficacy while minimizing the risk of chronic toxicity. We believe that intermittent dosing protocols should be reserved for high risk prevention protocols (see ROOT 9) and prophylactic protocols following NED (see forthcoming protocols).
3. Higher-dose protocols
Higher doses have occasionally been used in refractory disease…. The key word here is refractory disease.
Reported ranges:
- 0.6–1.0 mg/kg/day
However:
- clinical experience is limited,
- long-term safety data are lacking,
- these doses should be undertaken only with careful supervision.
Dosing Within the Five-Axis Metabolic Framework
Within the 8-week rotational model, ivermectin is often used continuously while other components rotate.
Weeks 1–4 (Mitochondrial/CSC Block)
- Ivermectin: 0.2–0.4 mg/kg/day
- Doxycycline
- Curcumin
- EGCG
- Sulforaphane
- Resveratrol
Weeks 5–8 (Mitotic Block)
- Ivermectin: continue 0.2–0.4 mg/kg/day
- Mebendazole
- Curcumin
- EGCG
- Sulforaphane
- Resveratrol
Why is ivermectin usually continued?
Unlike doxycycline and mebendazole, ivermectin has a broad multi-target profile, potentially affecting:
- PAK1 signaling,
- WNT/β-catenin,
- YAP/TAZ pathways,
- chloride channel regulation,
- cancer stem-cell biology,
- immune signaling,
- mitochondrial function,
- angiogenesis.
Because of this broad activity, many practitioners view ivermectin as a constant background pressure rather than an intervention requiring rotation.
Administration considerations
Ivermectin is generally taken:
- on an empty stomach, or
- 2 hours before or after meals.
However, because ivermectin absorption increases substantially with dietary fat, some clinicians intentionally administer it with food to improve systemic exposure. There is currently no consensus regarding the optimal approach in oncology.
Monitoring
Although ivermectin is generally well tolerated, prolonged use warrants periodic monitoring.
Suggested assessments include:
- Complete blood count,
- Liver function tests,
- Renal function,
- Neurological symptoms,
- Drug interaction review.
Safety
The most commonly reported adverse effects include:
- nausea,
- dizziness,
- fatigue,
- headache,
- mild gastrointestinal upset.
Less commonly:
- elevated liver enzymes,
- rash,
- neurological symptoms (usually associated with very high doses or interacting medications).
Ivermectin neurotoxicity
Neurotoxicity is the principal dose-limiting toxicity of ivermectin but is rare at conventional therapeutic doses. Under normal circumstances, ivermectin is actively excluded from the central nervous system by the P-glycoprotein (ABCB1/MDR1) transporter at the blood-brain barrier, resulting in minimal drug penetration into the brain.
However, at very high doses, or in situations where P-glycoprotein function is impaired by genetic variants, severe liver dysfunction, blood-brain barrier disruption, or interacting medications, ivermectin may accumulate in the CNS and enhance GABA-mediated inhibitory neurotransmission.
The clinical manifestations of neurotoxicity range from mild dizziness, drowsiness, blurred vision, tremor, and ataxia to confusion, dysarthria, seizures, coma, and, rarely, respiratory depression and death.
Most reported cases have occurred following massive intentional doing, massive ingestion of veterinary formulations, or co-administration with potent P-glycoprotein or CYP3A4 inhibitors that markedly increase systemic exposure.
Potential interacting medications include potent inhibitors of P-glycoprotein (e.g., verapamil, amiodarone, quinidine, clarithromycin) and strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir), which may increase systemic exposure.
Clinicians should also exercise caution in patients with significant hepatic impairment or pre-existing neurological disease.
For patients receiving ivermectin as part of a multi-drug oncology protocol, careful dose escalation, avoidance of major drug interactions, and monitoring for early neurological symptoms are prudent.
Extreme caution needs to be exercised when using dosages greater than 1mg/kg and the patient monitored for signs of neurotoxicity. Early symptoms such as dizziness, imbalance, excessive somnolence, visual changes, or confusion should prompt reassessment of therapy and consideration of dose reduction.
A clear dose response relationship does not exist, and we therefore strongly suggest that the dose be titrated to a maximum of 0.8 -1.0 mg/kg. Overall, while ivermectin possesses a wide therapeutic index, neurotoxicity remains the principal dose-limiting toxicity at very high exposures, underscoring the importance of individualized dosing and careful clinical supervision.
A Practical approach to dosing Ivermectin
We typically begin treatment with approximately 0.3 mg/kg/day of ivermectin. There are several reasons for this. First, ivermectin is only one component of a comprehensive, multi-target treatment strategy that also includes metabolic therapies, other repurposed drugs, nutraceuticals, and lifestyle interventions.
Because multiple cancer pathways are targeted simultaneously, we rarely find it necessary to maximize the dose of any single agent from the outset. Many patients achieve meaningful clinical responses with moderate doses.
As an old pharmacology principle reminds us, the best dose of any medicine is the smallest dose that effectively controls the disease.
Second, ivermectin has a practical dose-limiting toxicity. As the dose increases, some patients develop neurological symptoms, most commonly visual disturbances such as blurred vision, difficulty focusing, or altered color perception.
These symptoms often determine the maximum tolerated dose long before theoretical pharmacologic limits are reached. When they occur, we simply reduce the dose until the symptoms resolve.
Our patients are monitored closely, and dosing is individualized. If the initial regimen produces an inadequate clinical or radiographic response, we cautiously increase the dose while carefully monitoring for toxicity. In practice, however, we rarely approach 1 mg/kg/day.
Although some clinicians have used doses in that range, our experience has made us increasingly cautious. One patient treated by a colleague developed significant neurotoxicity after receiving nearly 1 mg/kg/day for more than six weeks, with tremor, gait instability, confusion, impaired memory, and manic behavior.
Whether this reflected an unusual genetic susceptibility or the consequences of prolonged high exposure is impossible to know. What it reinforced, however, was medicine’s oldest principle: First, do no harm.
(this principle was totally ignored with the so-called Covid ‘vaccines’ – Ed)
It is also important to distinguish short-term from prolonged high-dose therapy. Short courses of high-dose ivermectin have been reported to be well tolerated in other clinical settings, including during the COVID-19 pandemic.
Cancer treatment is fundamentally different. Patients may receive ivermectin for months or even years, and there is very limited data regarding the long-term safety of sustained high-dose therapy.
Finally, one observation has consistently shaped our approach. In certain patients, ivermectin appears to have a striking anticancer effect, as though it is targeting a critical biological vulnerability unique to that individual’s tumor.
When this occurs, the response is often evident at relatively modest doses, and further dose escalation offers little additional benefit while increasing the risk of toxicity. Readers may recall the case of Paul Mann, whose widely metastatic prostate cancer responded dramatically without the need for extreme dosing.
Our philosophy is simple: start low, monitor carefully, escalate only when necessary, and never increase the dose simply because more seems better.
The objective is not to find the highest tolerated dose, but rather the lowest effective dose within a comprehensive multi-drug metabolic treatment program.
See more here substack.com